Safety and antiviral activity of pradefovir in patients with chronic hepatitis B virus infection:: 48-week analysis of a phase 2 study

被引：0
|
作者：
Lim, S. G.
Lee, K. S.
Chuang, W. L.
Hwang, S. G.
Cho, M.
Lai, M. Y.
Chao, Y. C.
Chang, T. T.
Han, K. H.
Lee, C. M.
Um, S. H.
Yeon, J. E.
Yang, S. S.
Teo, E. K.
Peng, C. Y.
Lin, H. H.
Yang, S. S.
Huo, T. I.
Nguyen, T.
Chen, T. Y.
Hu, K. Q.
Xu, Y.
Sullivan-Bolyai, J. Z.
机构：
[1] Natl Univ Singapore Hosp, Coll Med, Singapore 117548, Singapore
[2] Yonsei Univ, Seoul, South Korea
[3] Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan
[4] Bundang CHA Hosp, Kyonggi Do, South Korea
[5] Pusan Natl Univ Hosp, Pusan, South Korea
[6] Natl Taiwan Univ Hosp, Taipei, Taiwan
[7] Tri Serv Gen Hosp, Taipei, Taiwan
[8] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[9] Kaohsiung Chang Gung Mem Hosp, Med Ctr Anam, Kaohsiung Hsien, Taiwan
[10] Korea Univ, Med Ctr Kuro, Seoul, South Korea
[11] Korea Univ, Seoul, South Korea
[12] Cathay Gen Hosp, Taipei, Taiwan
[13] Changi Gen Hosp, Singapore, Singapore
[14] China Med Univ Hosp, Taichung, Taiwan
[15] Tzu Chi Gen Hosp, Hualien, Taiwan
[16] Taichung Vet Gen Hosp, Taichung, Taiwan
[17] Taipei Vet Gen Hosp, Taipei, Taiwan
[18] Res & Educ Inc, San Diego, CA USA
[19] Chung Shan Med Univ Hosp, Taichung, Taiwan
[20] Univ Calif Irvine, Orange, CA 92668 USA
[21] Valeant Res & Dev, Costa Mesa, CA USA
来源：
JOURNAL OF CLINICAL VIROLOGY | 2006年 / 36卷
关键词：
D O I：
暂无
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
引用
收藏
页码：S238 / S238
页数：1
相关论文
共 50 条
  • [1] Safety, tolerability and antiviral activity of pradefovir mesylate in patients with chronic hepatitis B virus infection:: 48-week analysis of a phase 2 study
    Lee, K. S.
    Lim, S. G.
    Chuang, W. L.
    Hwang, S. G.
    Cho, M.
    Lai, M. Y.
    Chao, Y. C.
    Chang, T. T.
    Han, K. H.
    Lee, C. M.
    Um, S. H.
    Yeon, J. E.
    Yang, S. S.
    Teo, E. K.
    Peng, C. Y.
    Lin, H. H.
    Yang, S. S.
    Huo, T. I.
    Nguyen, T.
    Chen, T. Y.
    Hu, K. Q.
    Xu, Y.
    Sullivan-Bolyai, J. Z.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S274 - S274
  • [2] Safety, tolerability, antiviral activity, and pharmacokinetics of pradefovir mesylate in patients with chronic hepatitis B virus infection: 24-week interim analysis of a phase 2 study
    Sullivan-Bolyai, J
    Lim, SG
    Lee, KS
    Chuang, WL
    Hwang, SG
    Cho, M
    Lai, MY
    Chao, YC
    Chang, TT
    Xu, Y
    HEPATOLOGY, 2005, 42 (04) : 751A - 751A
  • [3] EFFICACY AND SAFETY OF CLEVUDINE IN CHRONIC HEPATITIS B PATIENTS; A 48-WEEK PROSPECTIVE STUDY
    Kwon, So Young
    Ko, Soon-Young
    Choe, Won Hyeok
    Kim, Byung Kook
    Lee, Chang Hong
    HEPATOLOGY, 2008, 48 (04) : 730A - 730A
  • [4] Association of pharmacogenomics and pharmacokinetics with antiviral activity of Pradefovir for treatment of chronic hepatitis B infection
    Zhang, Hong
    Chen, Hong
    Li, Qingmei
    Niu, Junqi
    Ding, Yanhua
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E143 - E144
  • [5] Tenofovir versus Entecarvir in Antiviral-Naive Chronic Hepatitis B Patients: Preliminary 48-Week Results
    Yang, Young Joo
    Shim, Ju Hyun
    Kim, Hyung-Don
    Ha, Yeonjung
    Jun, Mi-Jung
    Lee, Seung Bum
    Yang, Jee Eun
    Kim, Gi-Ae
    Park, Eui Ju
    An, Jihyun
    Lee, Danbi
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Chung, Young-Hwa
    Lee, Yung Sang
    Suh, Dong Jin
    HEPATOLOGY, 2014, 60 : 1113A - 1113A
  • [6] Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection
    Janssen, Harry L.
    Lim, Young-Suk
    Kim, Hyung Joon
    Sowah, Leonard
    Tseng, Cheng-Hao
    Coffin, Carla S.
    Elkhashab, Magdy
    Ahn, Sang Hoon
    Nguyen, Anh-Hoa
    Chen, Diana
    Wallin, Jeffrey J.
    Fletcher, Simon P.
    McDonald, Circe
    Yang, Jenny C.
    Gaggar, Anuj
    Brainard, Diana M.
    Fung, Scott
    Kim, Yoon Jun
    Kao, Jia-Horng
    Chuang, Wan-Long
    Brooks, Anna E.
    Dunbar, P. Rod
    JHEP REPORTS, 2024, 6 (02)
  • [7] Safety, efficacy, and pharmacokinetics of pradefovir for the treatment of chronic hepatitis B infection
    Zhang, Hong
    Wu, Min
    Zhu, Xiaoxue
    Li, Cuiyun
    Li, Xiaojiao
    Jin, Weili
    Zhang, Dengke
    Chen, Hong
    Liu, Chengjiao
    Ding, Yanhua
    Niu, Junqi
    Liu, Jingrui
    ANTIVIRAL RESEARCH, 2020, 174
  • [8] Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis delta: An integrated safety analysis of 48-week data
    Freismuth, A.
    Asselah, T.
    Lampertico, P.
    Aleman, S.
    Bourliere, M.
    Streinu-Cercel, A.
    Bogomolov, P.
    Morozov, V.
    Stepanova, T.
    Lazar, S.
    Suri, V.
    Manuilov, D.
    Mercier, R-C
    Tseng, S.
    Ye, L.
    Flaherty, J. F.
    Osinusi, A. O.
    Brunetto, M.
    Wedemeyer, H.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 70 - 70
  • [9] Antiviral effects after 48-week therapy of pegylated IFNα-2a combined with adefovir dipivoxil, in HBeAg positive chronic hepatitis B patients
    Sun, Haixia
    Yan, Ying
    Mai, Li
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 730 - 730
  • [10] A phase II study in China of the safety & antiviral activity of entecavir in adults with chronic hepatitis B infection.
    Yao, GB
    Xu, DZ
    Wang, B
    Zhou, XQ
    Lei, BJ
    Zhang, DF
    Xu, D
    Liu, J
    MacDonald, L
    HEPATOLOGY, 2003, 38 (04) : 711A - 711A
12345